Copyright Reports & Markets. All rights reserved.

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Market Analysis by Type
    • 1.3.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type: 2020 VS 2026
    • 1.3.2 Intravenous
    • 1.3.3 Oral
    • 1.3.4 Subcutaneous
    • 1.3.5 Others
  • 1.4 Market by Application
    • 1.4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application: 2020 VS 2026
    • 1.4.2 Hospital
    • 1.4.3 Clinic
    • 1.4.4 Others
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Perspective (2015-2026)
  • 2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Growth Trends by Regions
    • 2.2.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Share by Regions (2015-2020)
    • 2.2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Regions (2021-2026)
  • 2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Industry Dynamic
    • 2.3.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends
    • 2.3.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
    • 2.3.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges
    • 2.3.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Market Size
    • 3.1.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue (2015-2020)
    • 3.1.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Players (2015-2020)
  • 3.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue
  • 3.4 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio
    • 3.4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2019
  • 3.5 Key Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Area Served
  • 3.6 Key Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Solution and Service
  • 3.7 Date of Enter into Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Type

  • 4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Type (2015-2020)
  • 4.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2021-2026)

5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Application

  • 5.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Application (2015-2020)
  • 5.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2015-2026)
  • 6.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2015-2020)
  • 6.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2015-2020)
  • 6.4 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2015-2026)
  • 7.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2015-2020)
  • 7.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2015-2020)
  • 7.4 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2015-2026)
  • 8.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2015-2020)
  • 8.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2015-2020)
  • 8.4 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia

9 Latin America

  • 9.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2015-2026)
  • 9.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2015-2020)
  • 9.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2015-2020)
  • 9.4 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2015-2026)
  • 10.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2015-2020)
  • 10.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2015-2020)
  • 10.4 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE

11Key Players Profiles

  • 11.1 F. Hoffmann-La Roche Ltd
    • 11.1.1 F. Hoffmann-La Roche Ltd Company Details
    • 11.1.2 F. Hoffmann-La Roche Ltd Business Overview
    • 11.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
    • 11.1.4 F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2015-2020))
    • 11.1.5 F. Hoffmann-La Roche Ltd Recent Development
  • 11.2 Alexion Pharmaceuticals
    • 11.2.1 Alexion Pharmaceuticals Company Details
    • 11.2.2 Alexion Pharmaceuticals Business Overview
    • 11.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
    • 11.2.4 Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2015-2020)
    • 11.2.5 Alexion Pharmaceuticals Recent Development
  • 11.3 RemeGen
    • 11.3.1 RemeGen Company Details
    • 11.3.2 RemeGen Business Overview
    • 11.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
    • 11.3.4 RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2015-2020)
    • 11.3.5 RemeGen Recent Development
  • 11.4 Nihon Pharmaceutical
    • 11.4.1 Nihon Pharmaceutical Company Details
    • 11.4.2 Nihon Pharmaceutical Business Overview
    • 11.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
    • 11.4.4 Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2015-2020)
    • 11.4.5 Nihon Pharmaceutical Recent Development
  • 11.5 Harbour BioMed
    • 11.5.1 Harbour BioMed Company Details
    • 11.5.2 Harbour BioMed Business Overview
    • 11.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
    • 11.5.4 Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2015-2020)
    • 11.5.5 Harbour BioMed Recent Development
  • 11.6 Lundbeck
    • 11.6.1 Lundbeck Company Details
    • 11.6.2 Lundbeck Business Overview
    • 11.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
    • 11.6.4 Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2015-2020)
    • 11.6.5 Lundbeck Recent Development
  • 11.7 Bionure
    • 11.7.1 Bionure Company Details
    • 11.7.2 Bionure Business Overview
    • 11.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
    • 11.7.4 Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2015-2020)
    • 11.7.5 Bionure Recent Development
  • 11.8 Opexa Therapeutics
    • 11.8.1 Opexa Therapeutics Company Details
    • 11.8.2 Opexa Therapeutics Business Overview
    • 11.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
    • 11.8.4 Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2015-2020)
    • 11.8.5 Opexa Therapeutics Recent Development
  • 11.9 TG Therapeutics
    • 11.9.1 TG Therapeutics Company Details
    • 11.9.2 TG Therapeutics Business Overview
    • 11.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
    • 11.9.4 TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2015-2020)
    • 11.9.5 TG Therapeutics Recent Development
  • 11.10 Bio-Thera Solutions
    • 11.10.1 Bio-Thera Solutions Company Details
    • 11.10.2 Bio-Thera Solutions Business Overview
    • 11.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
    • 11.10.4 Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2015-2020)
    • 11.10.5 Bio-Thera Solutions Recent Development
  • 11.11 Boston Pharmaceuticals
    • 10.11.1 Boston Pharmaceuticals Company Details
    • 10.11.2 Boston Pharmaceuticals Business Overview
    • 10.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
    • 10.11.4 Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2015-2020)
    • 10.11.5 Boston Pharmaceuticals Recent Development
  • 11.12 Cour Pharmaceutical
    • 10.12.1 Cour Pharmaceutical Company Details
    • 10.12.2 Cour Pharmaceutical Business Overview
    • 10.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
    • 10.12.4 Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2015-2020)
    • 10.12.5 Cour Pharmaceutical Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Neuromyelitis Optica Spectrum Disorder (NMOSD) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Intravenous
    Oral
    Subcutaneous
    Others

    Market segment by Application, split into
    Hospital
    Clinic
    Others

    Based on regional and country-level analysis, the Neuromyelitis Optica Spectrum Disorder (NMOSD) market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    In the competitive analysis section of the report, leading as well as prominent players of the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    F. Hoffmann-La Roche Ltd
    Alexion Pharmaceuticals
    RemeGen
    Nihon Pharmaceutical
    Harbour BioMed
    Lundbeck
    Bionure
    Opexa Therapeutics
    TG Therapeutics
    Bio-Thera Solutions
    Boston Pharmaceuticals

    Buy now